Sorption-desorption behaviour of uranium (U), cesium (Cs) and strontium (Sr) was examined by quantification of the solid-liquid distribution coefficients (K(d)) using batch method in typical podzol soils from Ukraine. The effect of different physico-chemical parameters of soil on K(d) values has been discussed. Sorption reversibility has been tested by single extraction test. U shows reversible sorption and there was no isotopic fractionation observed with a known isotopic U composition using as tracer. Cs sorption mostly occurred in an irreversible manner. The clay content and exchangeable potassium in soil play an important role in Cs fixation. Sr adsorption is observed to be reversible and mainly controlled by cation exchange and shows highest mobility in the soil-water system. The K(d) values are found in the decreasing order U (log K(d) ≈ 2-3) > Cs (log K(d) ≈ 2) > Sr (log K(d) ≈ 1).

Download full-text PDF

Source
http://dx.doi.org/10.1093/rpd/ncs230DOI Listing

Publication Analysis

Top Keywords

log ≈
12
uranium cesium
8
cesium strontium
8
typical podzol
8
podzol soils
8
soils ukraine
8
sorption-desorption characteristics
4
characteristics uranium
4
strontium typical
4
ukraine sorption-desorption
4

Similar Publications

Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring germline BRCA mutations in Italy, where olaparib is not reimbursed for this indication.

Methods: Clinico/pathological data of pancreatic cancer patients with documented BRCA1-2 germline pathogenic variants who had received first-line chemotherapy for metastatic disease were collected from 23 Italian oncology departments and the impact of olaparib exposure on overall survival (OS) was analyzed.

View Article and Find Full Text PDF

Purpose: This retrospective analysis evaluates baseline F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [Lu]Lu-PSMA-I&T.

Methods: A total of 188 mCRPC patients with baseline F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics.

View Article and Find Full Text PDF

Myocardial infarction (MI) is a multifactorial polygenic disease that develops as a result of a complex interaction of numerous genetic factors and the external environment. Accordingly, the contribution of each of them separately is usually not large and may significantly depend on the state of other accompanying factors. The purpose of the study was to search for informative predictors of MI risk based on polygenic analysis of polymorphic variants of (1) the antioxidant defense enzyme genes PON1 (rs662), PON2 (rs7493), CAT (rs1001179), MSRA (rs10098474) and GSTP1 (rs1695); (2) the apoptosis genes CASP8 (rs3834129), TP53 (rs1042522) and BCL2 (rs12454712); and (3) the inflammation genes CRP (rs1205), CX3CR1 (rs3732378), IL6 (rs1800795) and CCL2 (rs1024611).

View Article and Find Full Text PDF

This study aimed to obtain paraprobiotics from Bifidobacterium animalis subsp. lactis Bb-12 (BB) presenting optimized antimicrobial activity against Salmonella enterica (SE). The paraprobiotics of BB (BBP) were obtained using ohmic heating (OH) under different conditions, and their effects on critical features of Salmonella, such as bacterial growth, biofilm formation, and adherence to Caco-2 cells, were studied.

View Article and Find Full Text PDF
Article Synopsis
  • - Enfortumab vedotin (EV) is effective for patients with advanced urothelial carcinoma who have previously received platinum chemotherapy and immune therapy, despite lacking research on those treated with avelumab maintenance.
  • - A study of 182 patients showed a median overall survival of 12.7 months and a progression-free survival of 7.9 months, with 39% achieving a positive response to EV after avelumab treatment.
  • - The study confirms EV's effectiveness, suggesting it can be a viable option for patients previously treated with avelumab, with manageable side effects like grade ≥ 3 neuropathy and skin rash occurring in a minority of cases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!